PCMTD1

Summary

PCMTD1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1, HGNC:30483) is a protein-coding gene on chromosome 8q11.23, encoding Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 (Q96MG8). Substrate recognition component of an ECS (Elongin BC-CUL5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.

Enables ubiquitin-like ligase-substrate adaptor activity. Involved in protein ubiquitination. Part of Cul5-RING ubiquitin ligase complex.

Source: NCBI Gene 115294 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 28 total
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 1 cancer types
• MANE Select transcript: NM_052937

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30483
Approved symbol	PCMTD1
Name	protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1
Location	8q11.23
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10883
Ensembl gene	ENSG00000168300
Ensembl biotype	protein_coding
OMIM	620091
Entrez	115294

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 15 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000360540, ENST00000519554, ENST00000519559, ENST00000519975, ENST00000521046, ENST00000521344, ENST00000522514, ENST00000544451, ENST00000883489, ENST00000883490, ENST00000952614, ENST00000952615, ENST00000952616, ENST00000952617, ENST00000952618, ENST00000952619, ENST00000952620, ENST00000952621

RefSeq mRNA: 4 — MANE Select: NM_052937 NM_001286782, NM_001286783, NM_001363193, NM_052937

CCDS: CCDS6148, CCDS69480

Canonical transcript exons

ENST00000522514 — 6 exons

Exon	Start	End
ENSE00001375470	51860845	51861246
ENSE00002100190	51817583	51820718
ENSE00002123365	51898930	51899036
ENSE00003531477	51845661	51845763
ENSE00003624796	51831444	51831567
ENSE00003661870	51833518	51833689

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 41.6414 / max 540.3930, expressed in 1805 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
93024	28.1511	1794
93025	11.5459	1701
93026	1.4617	602
93020	0.2304	73
93027	0.1537	79
93021	0.0986	30

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oviduct epithelium	UBERON:0004804	99.53	gold quality
tendon of biceps brachii	UBERON:0008188	99.20	gold quality
cardiac muscle of right atrium	UBERON:0003379	99.06	gold quality
left ventricle myocardium	UBERON:0006566	99.04	gold quality
upper arm skin	UBERON:0004263	98.97	gold quality
parotid gland	UBERON:0001831	98.92	gold quality
kidney epithelium	UBERON:0004819	98.90	gold quality
vastus lateralis	UBERON:0001379	98.89	gold quality
tendon	UBERON:0000043	98.88	gold quality
epithelial cell of pancreas	CL:0000083	98.79	gold quality
calcaneal tendon	UBERON:0003701	98.70	gold quality
amniotic fluid	UBERON:0000173	98.66	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.66	gold quality
visceral pleura	UBERON:0002401	98.60	gold quality
deltoid	UBERON:0001476	98.57	gold quality
parietal pleura	UBERON:0002400	98.52	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.36	gold quality
biceps brachii	UBERON:0001507	98.32	gold quality
seminal vesicle	UBERON:0000998	98.29	gold quality
germinal epithelium of ovary	UBERON:0001304	98.29	gold quality
buccal mucosa cell	CL:0002336	98.17	gold quality
quadriceps femoris	UBERON:0001377	98.08	gold quality
myocardium	UBERON:0002349	98.06	gold quality
renal medulla	UBERON:0000362	98.04	gold quality
epithelium of nasopharynx	UBERON:0001951	98.02	gold quality
tongue	UBERON:0001723	97.95	gold quality
skeletal muscle tissue	UBERON:0001134	97.88	gold quality
superior surface of tongue	UBERON:0007371	97.83	gold quality
cardia of stomach	UBERON:0001162	97.82	gold quality
body of tongue	UBERON:0011876	97.79	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-11	yes	248.69
E-ANND-3	yes	14.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

185 targeting PCMTD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-3065-5P	99.97	71.56	3281

Literature-anchored findings (GeneRIF, showing 7)

• Presence of at least one A allele (AG or AA genotype) for rs1015213 was associated with a shallower anterior chamber depth (-0.07 mm, 95% CI -0.01 to -0.14 mm, p=0.028) after adjusting for age and sex (both p</=0.001). (PMID:23505305)
• In our study, rs1015213 (located in the intergenic region between PCMTD1 and ST18) was associated significantly with primary angle closure. (PMID:23847314)
• The three genetic susceptibility loci for primary angle-closure glaucoma did not underlie any major phenotypic diversity in terms of disease severity or progression. (PMID:24474268)
• No significant association of PLEKHA7 rs11024102, COL11A1 rs3753841 and PCMTD1-ST18 rs1015213 with primary angle closure glaucoma was found among ethnic Han Chinese from Sichuan (PMID:27455018)
• In this study, 2 of 8 (primary angle-closure glaucoma) PACG-associated loci were associated significantly with PACS status, the earliest stage in the angle-closure glaucoma disease course. The association of these PACG loci with PACS status suggests that these loci may confer susceptibility to a narrow angle configuration. (PMID:29310965)
• This study has identified an increased percentage of IDH1 and PCMTD1 mutations in Squamous Cell Lung Cancers arising in the Appalachian Kentucky residents versus The Cancer Genome Atlas, with population-specific implications for the personalized treatment of this disease. (PMID:30377206)
• Human Protein-l-isoaspartate O-Methyltransferase Domain-Containing Protein 1 (PCMTD1) Associates with Cullin-RING Ligase Proteins. (PMID:35486881)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Pcmtd1	ENSMUSG00000051285
rattus_norvegicus	Pcmtd1	ENSRNOG00000005730
caenorhabditis_elegans	R119.5	WBGENE00020090

Paralogs (2): PCMT1 (ENSG00000120265), PCMTD2 (ENSG00000203880)

Protein

Protein identifiers

Protein-L-isoaspartate O-methyltransferase domain-containing protein 1 — Q96MG8 (reviewed: Q96MG8)

All UniProt accessions (3): E5RGG7, Q96MG8, H0YBU4

UniProt curated annotations — full annotation on UniProt →

Function. Substrate recognition component of an ECS (Elongin BC-CUL5-SOCS-box protein) E3 ubiquitin ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Specifically binds to the methyltransferase cofactor S-adenosylmethionine (AdoMet) via the N-terminal AdoMet binding motif, but does not display methyltransferase activity. May provide an alternate maintenance pathway for modified proteins by acting as a damage-specific E3 ubiquitin ligase adaptor protein.

Subunit / interactions. Component of the probable ECS(PCMTD1) E3 ubiquitin-protein ligase complex, at least composed of CUL5, ELOB, ELOC, RBX2 and PCMTD1. Interacts (via the BC-box) with ELOB and ELOC; the interaction is direct and stabilizes PCMTD1.

Subcellular location. Cytoplasm. Membrane.

Domain organisation. At its N-terminus, contains L-isoaspartate and S-adenosylmethionine (AdoMet) binding motifs. Also contains an extended SOCS box motif, where the Cul-box is separated from the BC-box by ~90 residues, within its C-terminus.

Similarity. Belongs to the methyltransferase superfamily. L-isoaspartyl/D-aspartyl protein methyltransferase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96MG8-1	1	yes
Q96MG8-2	2

RefSeq proteins (4): NP_001273711, NP_001273712, NP_001350122, NP_443169* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000682	PCMT	Family
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily

Pfam: PF01135

UniProt features (15 total): region of interest 6, compositionally biased region 2, initiator methionine 1, chain 1, active site 1, lipid moiety-binding region 1, splice variant 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9OMA	ELECTRON MICROSCOPY	4.14
9OMF	ELECTRON MICROSCOPY	9.72

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96MG8-F1	83.90	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 64

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 195 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, TTTGTAG_MIR520D, CHUNG_BLISTER_CYTOTOXICITY_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, MEF2_02, LHX3_01, NKX61_01, MCBRYAN_PUBERTAL_BREAST_4_5WK_DN, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, DOUGLAS_BMI1_TARGETS_DN, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, CUI_TCF21_TARGETS_2_DN, chr8q11, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, TGGAAA_NFAT_Q4_01

GO Biological Process (2): protein ubiquitination (GO:0016567), protein modification process (GO:0036211)

GO Molecular Function (3): protein-L-isoaspartate (D-aspartate) O-methyltransferase activity (GO:0004719), ubiquitin-like ligase-substrate adaptor activity (GO:1990756), protein binding (GO:0005515)

GO Cellular Component (3): cytoplasm (GO:0005737), membrane (GO:0016020), Cul5-RING ubiquitin ligase complex (GO:0031466)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
protein modification by small protein conjugation	1
protein metabolic process	1
macromolecule modification	1
S-adenosylmethionine-dependent methyltransferase activity	1
protein carboxyl O-methyltransferase activity	1
enzyme-substrate adaptor activity	1
binding	1
intracellular anatomical structure	1
cullin-RING ubiquitin ligase complex	1

Protein interactions and networks

STRING

1066 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PCMTD1	PLEKHA7	Q6IQ23	728
PCMTD1	EEIG1	Q5T9C2	601
PCMTD1	COL11A1	P12107	593
PCMTD1	ST18	O60284	573
PCMTD1	DPM2	O94777	573
PCMTD1	EPDR1	Q9UM22	571
PCMTD1	C10orf53	Q8N6V4	519
PCMTD1	NTAQ1	Q96HA8	475
PCMTD1	STK31	Q9BXU1	436
PCMTD1	SLC25A32	Q9H2D1	435
PCMTD1	PUS7	Q96PZ0	419
PCMTD1	ZNF605	Q86T29	417
PCMTD1	SCAF11	Q99590	407
PCMTD1	FERMT2	Q96AC1	401
PCMTD1	ZSCAN29	Q8IWY8	399

IntAct

25 interactions, top by confidence:

A	B	Type	Score
CUL5	SOCS2	psi-mi:“MI:0914”(association)	0.880
CUL5	SOCS6	psi-mi:“MI:0914”(association)	0.640
CUL5	SOCS7	psi-mi:“MI:0914”(association)	0.640
PPP2R3A	WTIP	psi-mi:“MI:0914”(association)	0.640
PCMTD1	PRKN	psi-mi:“MI:0915”(physical association)	0.560
RNF7	SOCS7	psi-mi:“MI:0914”(association)	0.530
Tipin	RPA2	psi-mi:“MI:0915”(physical association)	0.400
PCMTD1	PA	psi-mi:“MI:0915”(physical association)	0.400
JUN	TPM3	psi-mi:“MI:0914”(association)	0.350
CUL5	DDX3X	psi-mi:“MI:0914”(association)	0.350
RPS14	RRP8	psi-mi:“MI:0914”(association)	0.350
SEPTIN3	SEPTIN4	psi-mi:“MI:0914”(association)	0.350
MRPS11	HNRNPR	psi-mi:“MI:0914”(association)	0.350
	AP3B1	psi-mi:“MI:0914”(association)	0.350
LINC02912	USP9Y	psi-mi:“MI:0914”(association)	0.350
RNF7	SOCS2	psi-mi:“MI:0914”(association)	0.350
RPS14	NVL	psi-mi:“MI:0914”(association)	0.350
MRPS11	DBT	psi-mi:“MI:0914”(association)	0.350
ESRRG	TTR	psi-mi:“MI:0914”(association)	0.350
PCMTD1	SCHIP1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (30): PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Reconstituted Complex), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-MS), PCMTD1 (Affinity Capture-RNA)

ESM2 similar proteins: A2VDP2, A3KMI0, B2RR83, B4NBB0, D3ZA12, F8VPZ3, O43314, O60678, P19838, P25799, P41229, P41230, P51186, P59913, Q04861, Q10003, Q14BI7, Q17902, Q1LXK4, Q1LXK5, Q29RZ2, Q38JA7, Q3MHU3, Q58CZ2, Q5NVL7, Q5R746, Q5R7E5, Q5R7K4, Q5REW0, Q5ZMR3, Q62240, Q63369, Q6BX78, Q6F3J0, Q6IQX0, Q6J5K9, Q7K175, Q7Z478, Q80Y84, Q8BHD8

Diamond homologs: A2VDP2, A7HHV3, P59913, Q11TS0, Q58CZ2, Q5R7E5, Q5R7K4, Q5ZMR3, Q8BHD8, Q96MG8, Q9NV79, A8AAV7, B1L6T9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 28 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
proteasome-mediated ubiquitin-dependent protein catabolic process	5	10.4×	5e-03
protein ubiquitination	6	9.9×	3e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 1 cancer types — AML.

Clinical variants and AI predictions

ClinVar

28 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2257 predictions. Top by Δscore:

Variant	Effect	Δscore
8:51820719:C:CC	acceptor_gain	1.0000
8:51831438:AC:A	donor_loss	1.0000
8:51831439:CTTA:C	donor_loss	1.0000
8:51831440:TTAC:T	donor_loss	1.0000
8:51831441:TACGG:T	donor_loss	1.0000
8:51831442:A:AC	donor_gain	1.0000
8:51831442:A:C	donor_loss	1.0000
8:51831443:C:CA	donor_gain	1.0000
8:51831443:CG:C	donor_gain	1.0000
8:51831443:CGG:C	donor_gain	1.0000
8:51831443:CGGA:C	donor_gain	1.0000
8:51831443:CGGAG:C	donor_gain	1.0000
8:51831563:GTTAA:G	acceptor_gain	1.0000
8:51831564:TTAA:T	acceptor_gain	1.0000
8:51831565:TAA:T	acceptor_gain	1.0000
8:51831566:AA:A	acceptor_gain	1.0000
8:51831568:C:CC	acceptor_gain	1.0000
8:51831570:A:C	acceptor_gain	1.0000
8:51831572:T:C	acceptor_gain	1.0000
8:51831572:T:TC	acceptor_gain	1.0000
8:51833513:GTTAC:G	donor_loss	1.0000
8:51833514:TTACC:T	donor_loss	1.0000
8:51833515:TA:T	donor_loss	1.0000
8:51833516:ACCTG:A	donor_loss	1.0000
8:51833517:C:CA	donor_loss	1.0000
8:51833685:CAAAT:C	acceptor_gain	1.0000
8:51833689:TCTGC:T	acceptor_loss	1.0000
8:51833690:C:A	acceptor_loss	1.0000
8:51833690:C:CC	acceptor_gain	1.0000
8:51833695:T:C	acceptor_gain	1.0000

AlphaMissense

2375 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:51820670:C:G	R252P	1.000
8:51831502:A:C	F216L	1.000
8:51831502:A:T	F216L	1.000
8:51831503:A:C	F216C	1.000
8:51831503:A:G	F216S	1.000
8:51831504:A:C	F216V	1.000
8:51831504:A:G	F216L	1.000
8:51831504:A:T	F216I	1.000
8:51831509:A:T	V214D	1.000
8:51831510:C:G	V214L	1.000
8:51831534:A:G	W206R	1.000
8:51831534:A:T	W206R	1.000
8:51831551:C:G	R200P	1.000
8:51831566:A:G	L195S	1.000
8:51833531:G:C	P190R	1.000
8:51833531:G:T	P190H	1.000
8:51833532:G:A	P190S	1.000
8:51833532:G:T	P190T	1.000
8:51833537:A:T	V188D	1.000
8:51833546:C:A	G185V	1.000
8:51833546:C:T	G185D	1.000
8:51833547:C:G	G185R	1.000
8:51833558:A:G	L181P	1.000
8:51833600:G:T	A167D	1.000
8:51833603:C:T	G166E	1.000
8:51833604:C:G	G166R	1.000
8:51833604:C:T	G166R	1.000
8:51833605:A:C	C165W	1.000
8:51833606:C:T	C165Y	1.000
8:51833607:A:G	C165R	1.000

dbSNP variants (sampled 300 via entrez): RS1000005616 (8:51823081 G>A), RS1000020008 (8:51869804 T>A), RS1000081060 (8:51898277 C>G), RS1000114371 (8:51821968 C>T), RS1000196532 (8:51880094 G>A), RS1000205483 (8:51863963 TG>T), RS1000232923 (8:51822757 A>T), RS1000297275 (8:51839513 C>T), RS1000340043 (8:51851787 C>G,T), RS1000370808 (8:51897358 A>G), RS1000380117 (8:51857789 T>C), RS1000454333 (8:51863960 G>C), RS1000480822 (8:51891905 T>C), RS1000513555 (8:51829054 T>C), RS1000534210 (8:51892115 T>C)

Disease associations

OMIM: gene MIM:620091 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST003467_14	Glaucoma (primary angle closure)	5.000000e-16
GCST003467_15	Glaucoma (primary angle closure)	2.000000e-13
GCST006041_23	Major depressive disorder	2.000000e-07
GCST007559_22	Sleep duration (short sleep)	2.000000e-08
GCST009391_1021	Metabolite levels	9.000000e-06
GCST009391_1973	Metabolite levels	9.000000e-06
GCST009600_72	Anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy)	3.000000e-08
GCST011011_64	Youthful appearance (self-reported)	4.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0010360	lysophosphatidylcholine 18:1 measurement
EFO:0010541	trimethylamine-N-oxide measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, affects cotreatment	8
trichostatin A	affects cotreatment, decreases expression, affects expression	4
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	4
bisphenol A	decreases methylation, increases expression	2
entinostat	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Cyclosporine	decreases expression, increases expression	2
aristolochic acid I	decreases expression, increases expression	1
FR900359	increases phosphorylation	1
dicrotophos	decreases expression	1
beta-lapachone	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
phenethyl isothiocyanate	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
(+)-JQ1 compound	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Dasatinib	increases expression	1
Vorinostat	decreases expression	1
Panobinostat	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression	1
Arsenic	increases abundance, affects cotreatment, decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Clorgyline	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.